550 related articles for article (PubMed ID: 25491492)
21. Anti-interleukin-6 therapy in rheumatoid arthritis.
Woodrick R; Ruderman EM
Bull NYU Hosp Jt Dis; 2010; 68(3):211-7. PubMed ID: 20969554
[TBL] [Abstract][Full Text] [Related]
22. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?
Moots RJ; Ostör AJ; Isaacs JD
Expert Opin Investig Drugs; 2009 Nov; 18(11):1687-99. PubMed ID: 19715449
[TBL] [Abstract][Full Text] [Related]
23. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis.
Kondo N; Fujisawa J; Endo N
Tohoku J Exp Med; 2020 May; 251(1):9-18. PubMed ID: 32404541
[TBL] [Abstract][Full Text] [Related]
24. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
Tanaka Y; Takeuchi T; Amano K; Saito K; Hanami K; Nawata M; Fukuyo S; Kameda H; Kaneko Y; Kurasawa T; Nagasawa H; Hoshi D; Sato E; Yamanaka H
Mod Rheumatol; 2014 May; 24(3):399-404. PubMed ID: 24252045
[TBL] [Abstract][Full Text] [Related]
25. Tocilizumab in the treatment of adult rheumatoid arthritis.
Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
[TBL] [Abstract][Full Text] [Related]
26. Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials.
Moots RJ; Sebba A; Rigby W; Ostor A; Porter-Brown B; Donaldson F; Dimonaco S; Rubbert-Roth A; van Vollenhoven R; Genovese MC
Rheumatology (Oxford); 2017 Apr; 56(4):541-549. PubMed ID: 28013198
[TBL] [Abstract][Full Text] [Related]
27. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
[TBL] [Abstract][Full Text] [Related]
28. Subcutaneous formulation of tocilizumab for treatment of rheumatoid arthritis.
Ogata A; Morita T; Yoshida Y; Tanaka T
Ther Deliv; 2015 Mar; 6(3):283-95. PubMed ID: 25853305
[TBL] [Abstract][Full Text] [Related]
29. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
30. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging.
Kobayashi H; Kobayashi Y; Giles JT; Yoneyama K; Nakajima Y; Takei M
J Rheumatol; 2014 Oct; 41(10):1916-21. PubMed ID: 25128513
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
Patel AM; Moreland LW
Drug Des Devel Ther; 2010 Oct; 4():263-78. PubMed ID: 21116333
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
33. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
34. Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.
Cacciapaglia F; Anelli MG; Rinaldi A; Fornaro M; Lopalco G; Scioscia C; Lapadula G; Iannone F
Mediators Inflamm; 2018; 2018():2453265. PubMed ID: 30405318
[TBL] [Abstract][Full Text] [Related]
35. Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Ogata A; Kato Y; Higa S; Maeda K
Expert Opin Drug Deliv; 2019 Jun; 16(6):639-648. PubMed ID: 31088167
[TBL] [Abstract][Full Text] [Related]
36. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
Smolen JS; Schoels MM; Nishimoto N; Breedveld FC; Burmester GR; Dougados M; Emery P; Ferraccioli G; Gabay C; Gibofsky A; Gomez-Reino JJ; Jones G; Kvien TK; Murakami M; Betteridge N; Bingham CO; Bykerk V; Choy EH; Combe B; Cutolo M; Graninger W; Lanas A; Martin-Mola E; Montecucco C; Ostergaard M; Pavelka K; Rubbert-Roth A; Sattar N; Scholte-Voshaar M; Tanaka Y; Trauner M; Valentini G; Winthrop KL; de Wit M; van der Heijde D
Ann Rheum Dis; 2013 Apr; 72(4):482-92. PubMed ID: 23172750
[TBL] [Abstract][Full Text] [Related]
37. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
Burmester GR; Choy E; Kivitz A; Ogata A; Bao M; Nomura A; Lacey S; Pei J; Reiss W; Pethoe-Schramm A; Mallalieu NL; Wallace T; Michalska M; Birnboeck H; Stubenrauch K; Genovese MC
Ann Rheum Dis; 2017 Jun; 76(6):1078-1085. PubMed ID: 28007755
[TBL] [Abstract][Full Text] [Related]
38. Clinical safety of tocilizumab in rheumatoid arthritis.
Bannwarth B; Richez C
Expert Opin Drug Saf; 2011 Jan; 10(1):123-31. PubMed ID: 21121872
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab: A Review in Rheumatoid Arthritis.
Scott LJ
Drugs; 2017 Nov; 77(17):1865-1879. PubMed ID: 29094311
[TBL] [Abstract][Full Text] [Related]
40. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]